Tim Van-Assche
Overview
Explore the profile of Tim Van-Assche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
183
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van-Assche T, Huygelen V, Crabtree M, Antoniades C
Curr Pharm Des
. 2012 Sep;
19(9):1626-37.
PMID: 23016713
Conventional therapeutic options to treat chronic angina pectoris are pharmacological interventions, coronary bypass surgery (CABG) and percutaneous coronary intervention (PCI). In animal models, it was shown that gene delivery strategies...
2.
Van-Assche T, Huygelen V, Crabtree M, Antoniades C
Curr Pharm Des
. 2011 Dec;
17(37):4210-23.
PMID: 22204379
The extensive cross-talk between the immune system and vasculature leading to the infiltration of immune cells into the vascular wall is a major step in atherogenesis. In this process, reactive...
3.
Antoniades C, Van-Assche T, Shirodaria C, Diesch J, Antonopoulos A, Lee J, et al.
Circulation
. 2009 Sep;
120(11 Suppl):S170-6.
PMID: 19752364
Background: The risk of atrial fibrillation (AF) after coronary bypass surgery has been related to redox state, inflammation, and ischemia. Platelet activation is common to all of these pathways. We...
4.
Antoniades C, Shirodaria C, Leeson P, Baarholm O, Van-Assche T, Cunnington C, et al.
Circulation
. 2009 Apr;
119(18):2507-15.
PMID: 19398669
Background: The role of circulating homocysteine as an atherosclerosis risk factor has recently been questioned. However, 5-methyl-tetrahydrofolate (5-MTHF), the circulating metabolite of folic acid participating in homocysteine metabolism, has direct...
5.
Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, et al.
Eur Heart J
. 2009 Mar;
30(9):1142-50.
PMID: 19297385
Background: Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), is considered to be a risk factor for atherosclerosis. However, the mechanisms relating ADMA with vascular function...